Login / Signup

Disability accrual in primary and secondary progressive multiple sclerosis.

Sam Harding-ForresterIzanne RoosAi-Lan NguyenCharles B MalpasIbrahima DioufNahid MoradiSifat SharminGuillermo IzquierdoSara EichauFrancesco PattiDana HorakovaEva Kubala HavrdovaAlexandre PratMarc GirardPierre DuquetteFrancois Grand'MaisonMarco OnofrjAlessandra LugaresiPierre GrammondSerkan OzakbasMaria Pia AmatoOliver GerlachPatrizia SolaDiana FerraroKatherine BuzzardOlga SkibinaJeannette Lechner-ScottRaed AlroughaniCavit BozVincent Van PeschElisabetta CartechiniMurat TerziDavide MaimoneCristina Ramo-TelloBassem YamoutSamia Joseph KhouryDaniele La SpitaleriMaria Jose SaYolanda BlancoFranco GranellaMark SleeErnest ButlerYoussef SidhomRiadh GoudierRoberto BergamaschiRana KarabudakRadek AmpapaJosé Luis Sánchez-MenoyoJulie PrevostTamara Castillo TriviñoPamela A McCombeRichard MacdonellGuy LaureysLiesbeth Van HijfteJiwon OhAyse AltintasKoen de GansRecai TurkogluAnneke Van Der WaltHelmut ButzkuevenSteve VucicMichael BarnettEdgardo CristianoSuzanne HodgkinsonGerardo IulianoLudwig KapposJens KuhleVahid ShaygannejadAysun SoysalBianca Weinstock-GuttmanBart Van WijmeerschTomas Kalinciknull null
Published in: Journal of neurology, neurosurgery, and psychiatry (2023)
We demonstrate later onset of the progressive phase and slower disability accrual in SPMS versus PPMS. This may balance greater baseline disability in SPMS, yielding convergent disability trajectories across phenotypes. The different rates of disability accrual should be considered before amalgamating PPMS and SPMS in clinical trials.
Keyphrases
  • multiple sclerosis
  • white matter
  • clinical trial
  • depressive symptoms
  • open label